Compared to NVP, EFV is associated with a lower frequency of severe adverse events, in particular treatment discontinuations. This finding supports a move toward EFV-based therapy as the preferred first-line treatment regimen for HIV treatment within a public health approach.
No takes yet. Share an insight, caveat, or question.
Shubber et al. (2013) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: